Search Results for "reactive"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for reactive. Results 91 to 100 of 112 total matches.
Drugs for Hepatitis C Virus Infection
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
warning about a risk of
hepatitis B virus reactivation associated with their
use8; hepatitis B surface ...
About 2.5 million persons in the US had hepatitis C
between 2017 and 2020. Guidelines from the American
Association for the Study of Liver Diseases (AASLD)
and the Infectious Diseases Society of America (IDSA)
on management of hepatitis C virus (HCV) infection
were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74 doi:10.58347/tml.2024.1714a | Show Introduction Hide Introduction
Mercury in Fish
The Medical Letter on Drugs and Therapeutics • Dec 14, 2009 (Issue 1327)
consumption and markers of cardiovascular risk (e.g., C-reactive protein and high density lipoprotein ...
Recent news articles about mercury in fish may lead some patients to seek more information from their healthcare providers. For most Americans, seafood is the major source of exposure to mercury. The mercury in seafood is in the form of methylmercury, a potential neurotoxin formed by the organification of elemental mercury by marine microorganisms like plankton, which are then consumed by aquatic animals and concentrated up the food chain.
Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
reactivation
and emergence of drug resistance.
Summary: Cabotegravir/Rilpivirine (Cabenuva)
An extended ...
The FDA has approved Cabenuva (ViiV Healthcare),
an extended-release formulation of the new integrase
strand transfer inhibitor (INSTI) cabotegravir
copackaged with an extended-release formulation
of the non-nucleoside reverse transcriptase inhibitor
(NNRTI) rilpivirine, as a once-monthly complete
regimen for intramuscular (IM) treatment of adults
with HIV-1 infection who are virologically suppressed
(HIV-1 RNA...
Drugs for Smoking Cessation
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
decreased cell
viability, increased levels of reactive oxygen species, and
other markers of endothelial ...
Smoking tobacco remains the primary preventable
cause of death in the US. Smoking cessation often requires
both pharmacotherapy and behavioral support.
Natalizumab (Tysabri) for Relapsing Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Feb 14, 2005 (Issue 1202)
it
with azathioprine for Crohn’s disease. PML is an opportunistic infection of the brain, caused by reactivation ...
Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and glatiramer acetate are widely used for treatment of MS; they generally reduce the number of relapses by about 30% compared to placebo, and have been shown to be safe and effective for periods ranging from 4 to 10 years.
Thiazolidinediones and Cardiovascular Disease
The Medical Letter on Drugs and Therapeutics • Jul 16, 2007 (Issue 1265)
-reactive protein and
carotid intima-media thickness.
5,6
Pioglitazone has a
more favorable lipid ...
The thiazolidinediones rosiglitazone (Avandia) and pioglitazone (Actos) are peripheral insulin sensitizing agents used to treat hyperglycemia in patients with type 2 diabetes; one or the other is often used as a second or third agent with metformin (Glucophage, and others) and/or a sulfonylurea such as glimepiride (Amaryl, and others). A recent report suggested that rosiglitazone may increase the incidence of myocardial infarction (MI) and cardiovascular mortality.
Ocrelizumab (Ocrevus) for MS
The Medical Letter on Drugs and Therapeutics • Jun 19, 2017 (Issue 1523)
reactivation, hepatic
failure, and death; ocrelizumab is contraindicated for
use in patients with active HBV ...
The FDA has approved ocrelizumab (Ocrevus –
Genentech), a humanized anti-CD20 monoclonal
antibody, for treatment of adults with primary
progressive or relapsing multiple sclerosis (MS). It is the
first anti-CD20 monoclonal antibody to be approved for
treatment of MS and the first disease-modifying drug
to be approved in the US for primary progressive MS.
Expanded Table: Some Vaccines for Travelers (online only)
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018 (Issue 1560)
, and reactive
arthropathy have been reported
Yellow Fever
YF-Vax (Sanofi
Pasteur)15
0.5 mL SC (4.74 log10 ...
View the Expanded Table: Some Vaccines for Travelers
Drugs for Stable Angina Pectoris
The Medical Letter on Drugs and Therapeutics • Dec 09, 1994 (Issue 937)
cardioselective beta-blockers can produce severe
bronchospasm in patients with asthma or other reactive airway ...
Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the individual drugs, their dosage, and their cost.
Prevention and Treatment of Injury from Chemical Warfare Agents
The Medical Letter on Drugs and Therapeutics • Jan 07, 2002 (Issue 1121)
acetylcholinesterase reactivator that binds to the nerve agent, removing it from its binding site and reversing muscle ...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.